- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
People
Eva Canaan’s practice focuses on the strategic development and coordination of the scientific defense in pharmaceutical and medical device products liability litigation. In addition to her law degree, Eva holds a Masters in Epidemiology from Columbia University. Eva is adept at challenging expert witness testimony in depositions and Daubert briefs in federal and state courts.
Eva focuses on making complex scientific concepts accessible to judges and juries. She routinely works with experts in a variety of scientific disciplines, including epidemiology, toxicology, teratology, and clinical medicine. Going beyond bottom-line conclusions, Eva aggressively interrogates the data and methodology of studies and reports, often exposing flaws and weaknesses glossed over by the authors and plaintiffs’ experts. She has deposed plaintiffs’ main causation experts and drafted Daubert and Frye briefs in high-stakes litigations affecting hundreds of cases. Eva follows the epidemiological literature related to her clients’ products – both in and outside of the litigation context -- and provides real-time analyses and risk-assessments to her clients.
Credentials
M.S., Columbia University
J.D., Benjamin N. Cardozo School of Law
B.A., New York University, summa cum laude
New York
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
New York State Bar Association - Torts, Insurance and Compensation Law Section
Georgian
Russian
Close
Recognition
Named New York Metro Super Lawyers®
Rising Star, 2014
News
In the News · Source: Law.com
In the News · Source: Law360, Bloomberg Law, Financial Times, Reuters, The Deal, The National Law Journal and CDR
April 15, 2020
Life Sciences and Healthcare Litigation partner Eva Canaan joins the firm's Trial and Global Disputes practice group in New York
Press Release
April 14, 2020
King & Spalding Recruits Life Sciences and Healthcare Litigation Partner Eva Canaan in New York
Matters
Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).
Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).
Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.
See more
Close
Matters
Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).
Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).
Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.
Represented major pharmaceutical company in multidistrict litigation relating to allegations of heart attack and stroke from an anti-diabetic medication.
Insights
Article · Source: The New York Law Journal
March 11, 2021
The Importance of Epidemiology To Contextualize Safety Signals Associated With Women's Health Products
Client Alert
September 3, 2020
New FDA Guidance on Control of Nitrosamine Impurities
Article · Source: Law360
June 17, 2020
MDL Decisions Demonstrate The Need For Rule 702 Reform
News
In the News · Source: Law.com
In the News · Source: Law360, Bloomberg Law, Financial Times, Reuters, The Deal, The National Law Journal and CDR
April 15, 2020
Life Sciences and Healthcare Litigation partner Eva Canaan joins the firm's Trial and Global Disputes practice group in New York
Press Release
April 14, 2020
King & Spalding Recruits Life Sciences and Healthcare Litigation Partner Eva Canaan in New York
Matters
Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).
Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).
Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.
See more
Close
Matters
Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).
Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).
Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.
Represented major pharmaceutical company in multidistrict litigation relating to allegations of heart attack and stroke from an anti-diabetic medication.
Insights
Article · Source: The New York Law Journal
March 11, 2021
The Importance of Epidemiology To Contextualize Safety Signals Associated With Women's Health Products
Client Alert
September 3, 2020
New FDA Guidance on Control of Nitrosamine Impurities
Article · Source: Law360
June 17, 2020
MDL Decisions Demonstrate The Need For Rule 702 Reform
News
In the News · Source: Law.com
In the News · Source: Law360, Bloomberg Law, Financial Times, Reuters, The Deal, The National Law Journal and CDR
April 15, 2020
Life Sciences and Healthcare Litigation partner Eva Canaan joins the firm's Trial and Global Disputes practice group in New York
Press Release
April 14, 2020
King & Spalding Recruits Life Sciences and Healthcare Litigation Partner Eva Canaan in New York
Credentials
M.S., Columbia University
J.D., Benjamin N. Cardozo School of Law
B.A., New York University, summa cum laude
New York
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
New York State Bar Association - Torts, Insurance and Compensation Law Section
Georgian
Russian
Close
Recognition
Named New York Metro Super Lawyers®
Rising Star, 2014